This ‘Idiopathic Pulmonary Fibrosis - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough
There are several diagnostic tools available and the consensus guidelines have been well defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like x-rays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Idiopathic Pulmonary Fibrosis Understanding
Idiopathic Pulmonary Fibrosis Overview
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people in later stage of their life. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough
Idiopathic Pulmonary Fibrosis Diagnosis
Careful evaluation of clinical, laboratory, x-ray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathologic data.There are several diagnostic tools available and the consensus guidelines have been well defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like x-rays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Idiopathic Pulmonary Fibrosis Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis, and severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis scenario of Idiopathic Pulmonary Fibrosis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.Idiopathic Pulmonary Fibrosis Detailed Epidemiology Segmentation
- The total diagnosed prevalent cases of IPF in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019-2032).
- The highest diagnosed prevalent cases of IPF was accounted by the US in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.
- Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
- In the epidemiology model, the publisher has considered four age groups for the categorization of IPF i.e. 18-39 years, 40-59 years, 60-79 years, and >80 years. As per our analysis, a highest percentage of diagnosed prevalent cases was observed in age group 60-79, in all the 7MM countries.
- As per the analysis the males are predominantly affected highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.
- Japan accounted for 21,246 cases of total diagnosed prevalent cases of IPF in 2021 which are anticipated to rise by the end of 2032.
Scope of the Report
- The report covers the descriptive overview of Idiopathic Pulmonary Fibrosis, explaining its causes, signs, and symptoms, and pathophysiology.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden.
- The report provides the segmentation of the disease epidemiology for 7MM by segmented by diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis, and severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
Report Highlights
- 11-Year Forecast of Idiopathic Pulmonary Fibrosis.
- The 7MM Coverage.
- Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
- Gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
- Age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
- Severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
Key Questions Answered
- What are the disease risk, burdens, and unmet needs of Idiopathic Pulmonary Fibrosis?
- What is the historical Idiopathic Pulmonary Fibrosis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Idiopathic Pulmonary Fibrosis at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Idiopathic Pulmonary Fibrosis?
- Out of the countries mentioned above, which country would have the highest patient population of Idiopathic Pulmonary Fibrosis during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Idiopathic Pulmonary Fibrosis report will allow the user to -- Develop business strategies by understanding the trends shaping and driving the 7MMIdiopathic Pulmonary Fibrosis epidemiology.
- The Idiopathic Pulmonary Fibrosis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The Idiopathic Pulmonary Fibrosis epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Table of Contents
1. Key Insights2. Report Introduction4. Executive Summary of Idiopathic Pulmonary Fibrosis5. Key Events8. Patient Journey9. KOL Views11. Publisher Capabilities12. Disclaimer13. About the Publisher
3. Idiopathic Pulmonary Fibrosis Epidemiology Overview at a Glance
6. Disease Background and Overview of Idiopathic Pulmonary Fibrosis
7. Epidemiology and Patient Population
10. Appendix
List of Tables
List of Figures
